Senses Disorder TRIZ Cases

Replacing universal viral promoters with rod-specific sequences resolves the trade-off between high expression levels and cell-type specificity.

Allosteric pregnenolone derivatives block CB1 activation without orthosteric interference, reducing adverse effects from total inhibition.

Monodisperse hyaluronic acid polymers covalently link to anti-VEGF antibodies, extending ocular residence time and reducing intravitreal injection frequency.

Mono-substituted benzylideneguanidine derivatives eliminate alpha-2 adrenergic activity while preserving protective effects against protein misfolding diseases.

A quinazolinone derivative regulates TNF-α generation or activity through structural modification of the Lenalidomide core.

Hyaluronic acid conjugated with specific matrix metalloproteinase inhibitors resists enzymatic degradation while maintaining viscoelastic properties.

Engineered bispecific antibodies target VEGF-A and IL6 to treat ocular vascular diseases while reducing injection frequency.

Optimized pH and osmolality prevent peptide degradation and aggregation in dry eye treatments.

A low-concentration atropine ophthalmic composition treats near-work induced transient myopia using a specific pH adjusting agent.

Antibody-conjugated FGF21 suppresses pathological retinal and choroidal neovascularization while reducing safety concerns from frequent dosing.

Heptapeptide amides lower pathologically elevated HMGB1 to treat inflammatory diseases, addressing the lack of commercially available anti-HMGB1 agents.

Fusing melanopsin with mGluR6 domains creates a chimeric protein that couples light signals to intracellular cascades in retinal neurons.

Pyrazole compounds target peripheral CB1 receptors to treat metabolic disorders while avoiding psychiatric side effects from central nervous system exposure.

Amide-substituted indazoles resolve weak PARP inhibition and off-target effects by modifying molecular parameters to enhance binding affinity.

Cadherin-11 antagonists block fibroblast adhesion to reduce inflammatory cytokine levels.

Dihydrofuran derivatives modulate GPR119 receptors to lower blood glucose levels without causing hypoglycemia in diabetic patients.

Targeting soluble epoxide hydrolase reduces pathological vascular growth while avoiding systemic side effects of broad VEGF inhibition.

Combining 2,4-DSPBN with N-acetylcysteine mitigates oxidative stress and inflammation to preserve natural hearing mechanisms.

Selective compounds inhibit O-GlcNAcase to elevate O-GlcNAc levels, reducing tau hyperphosphorylation without affecting beta-hexosaminidases.

Mixing ground Tartary buckwheat with heated protein solution maximizes 4-Methyl-Catechol formation and bioavailability.

Recombinant adeno-associated virus delivers the RPGR gene to arrest vision loss in X-linked retinitis pigmentosa.

A cell aggregate culture method modulating Wnt and FGF signaling pathways to generate ciliary marginal zone-like structures with high efficiency.

A collagen type II alpha1 peptide reduces corneal angiogenesis and opacification in ocular surface disease models.

Deuterated droxidopa compounds use isotopic substitution to slow metabolism, reducing toxic metabolites and improving patient compliance.

Replacing di-p-toluoyl-L-tartaric acid with camphorsulfonic acid raises enantiomeric purity above 99% while cutting cis-diastereomer impurities below 1%.

Macrogol 15 hydroxystearate replaces polysorbate 80 to boost API solubility without triggering oxidative degradation.

Novel heterocyclic compounds replace phenyl rings to boost TRPV1 antagonistic activity and metabolic stability.

Dock-and-Lock technology directs single PEG attachment to protein N-termini, resolving mixture formation and preserving bioactivity.

Dual specificity antibody fusion proteins combine Fab fragments with single domain antibodies to enable simultaneous antigen binding.

Staged culture conditions guide embryoid body formation to produce purified RPE cells, resolving inefficiency in systematic differentiation.

Isoquinoline compounds stabilize defective protein folding and trafficking to restore ion transport in cystic fibrosis.

Extra-ocular botulinum toxin injection treats macular degeneration by blocking nerve signals to choroidal vessels, avoiding intra-ocular hemorrhage risks.

Phenanthrenequinone compounds activate AMPK to address limited effectiveness of existing metabolic syndrome treatments.

Carboxymethylcellulose and tyloxapol stabilize prostaglandin analogue eye drops at room temperature, eliminating benzalkonium chloride-induced dry eye.

Plant-based production of modified norovirus VP1 proteins overcomes cell culture limitations to boost yield and stability.

Selective S1P1 agonists reduce circulating T-cells to prevent organ rejection without compromising infection defense.

Tricyclic triazolic compounds resolve the contradiction between receptor affinity and solubility by modifying molecular structure to enhance bioavailability.

Merging ibudilast and riluzole into one dosage form overcomes insufficient efficacy of single agents while managing treatment complexity.

A fused imidazole compound selectively inhibits indoleamine 2,3-dioxygenase through specific structural parameters.

Compound C41 normalizes amyloid precursor protein processing to reduce neurotoxic Aβ peptides and improve cognitive symptoms in Alzheimer's disease.

Tetrahydropyridoether compounds eliminate lipofuscin from retinal pigment epithelium cells.

Saxitoxin analogues block sodium channels to relieve pain while labeled forms localize channel-enhanced ailments for objective diagnosis.

Selective CB2 receptor agonists treat inflammation and pain without psychoactive effects.

Interfering RNAs silence HIF1A mRNA expression, reducing ocular angiogenesis and retinal edema without permanent retinal damage from laser procedures.

Oxadiazole amine derivatives inhibit histone deacetylase 6 activity through targeted zinc-binding group modifications.

Controlled ATRP synthesis of siloxane copolymers resolves dimensional variations in disposable molds, ensuring high fidelity to original lens designs.

Aucuba japonica extract containing aucubin and aucubine inhibits lipofuscin photo-oxidation, addressing the lack of fundamental cures for macular degeneration.

Selective IP receptor antagonists block pre-formed prostaglandins to relieve pain from dry eye and corneal injuries.